Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Innovation Is… with Stephan Tanda, Managing Board Member, Royal DSM

ST-115x76

The term “innovation” is thrown around more often than Peyton Manning’s name during Fantasy Football season. But if any industry can truly capture the essence of innovation, it is the biotech industry. Innovation is inherent in what we do – from curing or treating illnesses that were once considered a death sentence to feeding a growing population to helping to reduce our dependence on foreign oil through the production of biofuels. But what is innovation, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

JOBS Act Deconstructed: Confidential Filing

AB23475

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. Any company conducting a public offering must file a registration statement, called an S-1, with the SEC.  The purpose of this document is to inform investors Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

JOBS Act Deconstructed: Testing-the-Waters

87881842

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. The JOBS Act enables companies to promote themselves to potential investors in advance of their IPO. Prior to the JOBS Act, companies conducting a public offering Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

UK Bioscience Forum: Confronting Common Challenges

Jim_London115x76

This week, BIO’s President and CEO Jim Greenwood delivered a plenary address to attendees at the UK Bioscience Forum in London, England. Below are excerpts from his speech: We can work together to build the right framework to support innovation. From the way we fund research, to how we protect innovations, to how we attract investment and streamline regulatory approval. The UK has the right innovation ecosystem in place to grow as a global biotech Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

95468934

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the patient community to guide the drug development process. “Patients should be providing input and guidance throughout the entire drug review process,” said Marc Boutin, Executive VP and COO of the National Health Council. Boutin highlighted the improvements made through PDUFA V to open up and enhance the Agency’s interaction and engagement with patients. “Integrating our perspective into how drugs are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,